5 April 2019 - - Belgium-based biotherapeutics company AgomAb Therapeutics N.V. has secured EUR 21m in a series A financing round from a strong international investor syndicate, the company said.

It also announces the exercise of an exclusive license agreement with argenx SE (NASDAQ: ARGX) and a number of senior appointments to its Leadership Team and board of directors.

AgomAb was founded in 2017 based on the groundbreaking work of Paolo Michieli and his translational medicine team at the University of Torino, Italy, who have been studying the biology of Hepatocyte Growth Factor for almost 20 years.

In collaboration with argenx, the company is developing growth factor-mimetic agonistic monoclonal antibodies with the potential to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating a range of applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases.

AgomAb was founded through a collaboration between argenx and the University of Torino, Italy, based on the groundbreaking work of Paolo Michieli and his translational medicine team.

The company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases.

Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors.